Verona Pharma plc diskutieren
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target lowered by analysts at HC Wainwright from $33.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $32.00 to $36.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Truist Financial Co. from $32.00 to $38.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Neueste Beiträge
BTIG_Research in Aerovironment diskutieren